ArticleFrontiers in medicine2026
Tracing the clinicodermoscopic and histopathological evolution of acquired reactive perforating collagenosis: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis that is frequently misdiagnosed, particularly before the development of overt transepidermal elimination. Although early lesions have been sporadically mentioned in previous reports, direct clinicopathological evidence supporting a recognizable pre-perforating stage remains limited. We report the case of a 64-year-old woman with a 3-year history of progressive, generalized pruritic papules and nodules, initially misdiagnosed as eczema and refractory to conventional treatments. The patient had long-standing type 2 diabetes mellitus and other metabolic comorbidities. Dermoscopy of early erythematous papules revealed subtle but reproducible features distinct from those of fully developed lesions. Notably, even in early lesions showing focal epidermal disruption, classic dermoscopic signs of perforation were absent. Targeted biopsy of these early lesions exhibited abnormal aggregation and disorganization of dermal collagen in the superficial dermis, closely apposed to the epidermis but without transepidermal elimination. In contrast, biopsies of mature umbilicated plaques revealed typical collagen extrusion with overlying keratotic plugs. Sequential Masson's trichrome and elastic fiber staining further supported a stepwise evolution from superficial collagen remodeling to overt perforation. By correlating dermoscopic findings with sequential histopathological changes in the same patient, this case report provides direct evidence that ARPC progresses through a definable pre-perforating stage, in which epidermal disruption alone is insufficient to induce collagen elimination. Recognition of this early stage has important implications for timely diagnosis, appropriate biopsy selection, and avoidance of prolonged misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.